Lymphoma Diagnosis and Treatment

This paper uses machine learning to classify B cell lymphomas based on BCR repertoire sequencing, achieving high accuracy in distinguishing between subtypes.

This study shows CD20 stabilizes CD37 on B-cell lymphoma cells, affecting anti-CD37 therapy efficacy, but not CAR-T cell effectiveness.

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

This study shows that targeting PSGL-1 with an antibody induces apoptosis in lymphoma cells and inhibits tumorigenesis in some models.

This study develops a xenograft model in avian embryos to study follicular lymphoma response to RCHOP therapy, identifying a gene signature and validating BAX as a key effector of treatment.

The paper develops a prognostic model using spatially resolved tumor microenvironment features to predict treatment outcomes in relapsed/refractory Hodgkin lymphoma.

This study uses ultra-deep exome sequencing to identify recurrent mutations in classical Hodgkin lymphoma HRS cells, demonstrating its utility for analyzing genomic variants in large patient cohorts.

This study identifies subtype-specific and co-occurring genetic alterations across major B-NHL subtypes using targeted sequencing of 380 genes in 685 tumors.

This study identifies genetic and pathologic features of t(14;18)-negative diffuse follicular lymphoma, showing recurrent 16p13 and 1p36 deletions, CREBBP and STAT6 mutations, and co-mutations.

This study identifies genetic drivers of mantle cell lymphoma through exome and genome sequencing, revealing novel mutations in genes involved in RNA splicing and regulation.

This study uses whole genome sequencing to identify potential familial Hodgkin lymphoma predisposing genes in three families, finding a novel DICER1 variant in one family.

The paper identifies TCF4 overexpression driven by 18q21.2 gains as a mechanism promoting IgM expression in ABC-like DLBCL and shows BET inhibitors can suppress it.

This study identifies somatic coding and regulatory variants in DLBCL, revealing novel mechanisms of oncogene deregulation and potential therapeutic targets.